Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8052741 | 0.80 | TLR4 (0.52) | TLR4TLR2MAPTPOLBCYP3A4 | |
| SCHEMBL12100240 | 0.80 | TLR4 (0.52) | TLR4TLR2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7355562 | 0.80 | TLR4 (0.52) | TLR4TLR2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL8557561 | 0.80 | TLR4 (0.52) | TLR4TLR2MAPTALDH1A1MEN1 | |
| SCHEMBL5431733 | 0.80 | TLR4 (0.52) | TLR4TLR2MAOBPOLBALDH1A1 | |
| SCHEMBL1371678 | 0.79 | MEN1 (0.50) | TLR4TLR2MAOBMAPTPOLB | |
| SCHEMBL2110045 | 0.78 | TLR4 (0.49) | TLR4TLR2MAPTTP53ALDH1A1 | |
| SCHEMBL11730823 | 0.78 | NR4A1 (0.53) | TLR4TLR2HSP90AA1ALDH1A1MEN1 | |
| SCHEMBL9367822 | 0.77 | TLR4 (0.47) | TLR4TLR2P2RX3 | |
| SCHEMBL2539410 | 0.76 | TLR4 (0.66) | TLR4TLR2MAOBMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748627-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-1999119-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | Abbott Laboratories (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC. | 2007-09-27 | — | — | US | disclosed |
| WO-2007095602-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | TLR4 3416/4885TLR2 2927/4885MAOB 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.